Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy

by Aura Muntasell, Mariona Cabo, Sonia Servitja, Sonia Servitja, Ignasi Tusquets, Ignasi Tusquets, María Martínez-García, María Martínez-García, Ana Rovira, Ana Rovira, Federico Rojo, Joan Albanell, Joan Albanell, Joan Albanell, Miguel López-Botet, Miguel López-Botet
Published 2017-11-01

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

by Sonia Servitja, Tamara Martos, Maria Rodriguez Sanz, Natalia Garcia-Giralt, Daniel Prieto-Alhambra, Laia Garrigos, Xavier Nogues, Ignasi Tusquets
Published 2015-09-01

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study

by Marta Pineda-Moncusí, Natalia Garcia-Giralt, Adolfo Diez-Perez, Ignasi Tusquets, Sonia Servitja, Joan Albanell, Daniel Prieto-Alhambra, Xavier Nogués
Published 2020-03-01

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

by Luis Manso, Cristina Hernando, María Galán, Mafalda Oliveira, Miguel A. Cabrera, Raquel Bratos, César A. Rodríguez, Manuel Ruiz-Borrego, Salvador Blanch, Antonio Llombart-Cussac, Juan I. Delgado-Mingorance, Iñaki Álvarez-Busto, Isabel Gallegos, Lucía González-Cortijo, Serafín Morales, Elena Aguirre, Blanca A. Hernando, Ana Ballesteros, José E. Alés-Martínez, Cristina Reboredo, Amparo Oltra, María González-Cao, Marta Santisteban, Diego Malón, Isabel Echeverría, Elisa García-Garre, Estela Vega, Sònia Servitja, Raquel Andrés, Carlos E. Robles, Rafael López, Elena Galve, María J. Echarri, Marta Legeren, Fernando Moreno
Published 2020-12-01